U.S., Sept. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07156565) titled 'Actinium Therapy for Late-stage Aggressive Sarcomas' on Jan. 17.
Brief Summary: The goal of this clinical trial is to learn about the safety of drug [Ac225]RTX-2358 and the diagnostic imaging agent [Cu64]LNTH-1363S. Additionally Ratio Therapeutics will learn if [Ac225]RTX-2358 drug is effective in treating advanced sarcoma.
The main questions the study aims to answer in Phase/Part 1 of the trial are:
* Is [Ac225]RTX-2358 tolerable or does it cause toxicities (medical problems) in patients.
* What is the most tolerable dose of [Ac225]RTX-2358
* Does the treatment show effectiveness on advanced sarcoma
Participants will:
* Take ...